Molecular targeting in oncology / ed. by Kaufman H.L., Wadler S., Antman K. - Totowa, NJ: Humana Press, 2008. - 728 p. - (Cancer drug discovery and development). - ISBN 978-1-58829-577-4  Место хранения:   01 | ГПНТБ СО РАН | Новосибирск

Оглавление / Contents

Introduction .................................................. vii Contributors ................................................. xiii Part I: General Strategies for Molecular Targeting in Oncology 1. The Cell Cycle: Therapeutic Targeting of Cell Cycle Regulatory Components and Effector Pathways in Cancer ....... 3 Chad D. Knights and Richard G. Pestell 2. mTOR: Properties and Therapeutics .......................... 33 John B. Easton and Peter J. Houghton 3. Ras/Raf/MEK Inhibitors ..................................... 55 Joseph A. Sparano 4. 17-AAG: Targeting the Molecular Chaperone Heat Shock Protein 90 ................................................. 75 Len Neckers and Percy Ivy 5. The Cancer Epigenome: Can it be Targeted for Therapy? ...... 97 Sam Thiagalingam and Douglas V. Faller Part II: Molecular Targeting for Specific Disease Sites 6. Molecular Targeting in Upper Gastrointestinal Malignancies .............................................. 117 Scott Wadler 7. Molecular Targeting of Colorectal Cancer: An Idea Whose Time Has Come ............................................. 133 Mark L. Sundermeyer, Alfonso Bellacosa, and Neal J. Meropol 8. Molecular Targeting in Hepatocellular Carcinoma ........... 165 Jonathan D. Schwartz and Josep M. Llovet 9. Molecularly Targeted Therapy in Pancreatic Cancer ......... 211 Anupama Goel and Peter Kozuch 10. Untargeted Use of Targeted Therapy: A Dilemma in Non-Small Cell Lung Cancer ................................ 227 Cheryl Ho, Angela M. Davies, Primo N. Lara, O. Gautschi, P.С. Mack, Paul H. Gumerlock, and David R. Gandara 11. Renal Cell Carcinoma: Renal Cell Cancer ................... 241 Olwen Hahn and Walter Stadler 12. Targeted Therapies for Prostate Cancer .................... 263 Elisabeth I. Heath and Michael A. Carducci 13. Molecular Targets in Ovarian Cancer and Endometrial Cancer .................................................... 291 Nilofer S. Azad, Gisele Sarosy, and Elise C. Kohn 14. Targeted Therapy For Breast Cancer ........................ 309 Deena M. Atieh and Linda T. Vahdat 15. Melanoma .................................................. 343 Akshay Gupta and John M. Kirkwood Part III: Classes of Drugs for Molecular Targeting in Oncology 16. Antibody Therapy of Cancer ................................ 371 Hossein Borghaei, Liat Binyamin, Igor Astsaturov, and Louis M. Weiner 17. Nucleic Acid Therapies for Cancer Treatment ............... 413 Dan T. Vogl and Alan M. Gewirtz 18. Engineering Oncolytic Measles Viruses for Targeted Cancer Therapy ............................................ 431 Takafumi Nakamura and Stephen J. Russell 19. Vaccines as Targeted Cancer Therapy ....................... 447 Miguel-Angel Perales, Jedd D. Wolchok, and Howard L. Kaufman 20. Cytokine-Based Therapy for Cancer ......................... 471 Henry B. Koon and Michael B. Atkins 21. Cyclooxygenase-2 as a Target for Cancer Prevention and Treatment ............................................. 509 Monica Bertagnolli, Jaye L. Viner, and Ernest T. Hawk Part IV: Specific Drugs for Molecular Targeting in Oncology 22. Imatinib Mesylate (Gleevec®) and the Emergence of Chemotherapeutic Drug-Resistant Mutations ................. 545 Gerald V. Denis 23. Development of a Targeted Treatment for Cancer: The Example of C225 (Cetuximab) ........................... 559 John Mendelsohn 24. VEGF Inhibition for Cancer Therapy ........................ 573 Shermini Saini and Herbert Hurwitz 25. Somatostatin Analogue Therapy ............................. 585 M.C. Champaneria, I.M. Modlin, I. Latich, J. Bornschein, I. Drozdov, and M. Kidd Part V: Challenges in Molecular Targeting in Oncology 26. Patient Selection for Rational Development of Novel Anticancer Agents ......................................... 641 Grace K. Dy and Alex A. Adjei 27. Clinical Trial Design with Targeted Agents ................ 649 Sarita Dubey and Joan H. Schiller 28. How to Define Treatment Success or Failure if Tumors Do Not Shrink: Consequences for Trial Design .............. 657 J.J.E.M. Kitzen, M.J.A. de Jonge, and J. Verweij 29. Molecular Imaging in Oncology ............................. 675 Lalitha K. Shankar, Anne Menkens, and Daniel C. Sullivan 30. Combinations of Molecular-Targeted Therapies: Opportunities and Challenges .............................. 693 Helen X. Chen and Janet E. Dancey 31. Preclinical Development of Molecularly Targeted Agents in Oncology ........................................ 707 Joseph E. Tomaszewski and James H. Doroshow Index ......................................................... 723